The latest price target for Cardiff Oncology (NASDAQ:CRDF) was reported by HC Wainwright & Co. on November 8, 2024. The analyst firm set a price target for $13.00 expecting CRDF to rise to within 12 months (a possible 379.69% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Cardiff Oncology (NASDAQ:CRDF) was provided by HC Wainwright & Co., and Cardiff Oncology maintained their buy rating.

There is no last upgrade for Cardiff Oncology

There is no last downgrade for Cardiff Oncology.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiff Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiff Oncology was filed on November 8, 2024 so you should expect the next rating to be made available sometime around November 8, 2025.

While ratings are subjective and will change, the latest Cardiff Oncology (CRDF) rating was a maintained with a price target of $14.00 to $13.00. The current price Cardiff Oncology (CRDF) is trading at is $2.71, which is out of the analyst’s predicted range.